Scandinavian clinical practice guideline on fluid and drug therapy in adults with acute respiratory distress syndrome

Main Editor Jon Henrik Laake
Language en
Last Update May 23, 2016
Published Date May 23, 2016
Contact
Disclaimer

Sponsors Scandinavian Society of Anesthesiology and Intensive Care Medicine
Abstract

The objective of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine (SSAI) task force on fluid and drug therapy in adults with acute respiratory distress syndrome (ARDS) was to provide clinically relevant, evidence-based treatment recommendations according to standards for trustworthy guidelines.

PICOS
PICO 5.1
P: Mechanically ventilated adults with acute respiratory distress syndrome (ARDS)
I: Restrictive fluid therapy
C: Liberal fluid therapy
O:

PICO 5.2
P: Mechanically ventilated adults with acute respiratory distress syndrome (ARDS)
I: Corticosteroids at any dose or duration and route of administration
C: Placebo or None
O:

PICO 5.3
P: Mechanically ventilated adults with acute respiratory distress syndrome (ARDS)
I: Beta2 agonists at any dose or duration and route of administration
C: Placebo or None
O:

PICO 5.4
P: Mechanically ventilated adults with acute respiratory distress syndrome (ARDS)
I: Neuromuscular blocking agents (NMBAs) at any dose or duration
C: Placebo or None
O:

PICO 5.5
P: Mechanically ventilated adults with acute respiratory distress syndrome (ARDS)
I: Inhaled nitric oxide (iNO)
C: Placebo or None
O:

PICO 5.6
P: Mechanically ventilated adults with acute respiratory distress syndrome (ARDS)
I: Prostanoids at any dose and any route of administration
C: Placebo or None
O:

PICO 5.7
P: Mechanically ventilated adults with acute respiratory distress syndrome (ARDS)
I: Statins in any dose or route of administration
C: Placebo or None
O: